特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

注目市場の分析:神経内分泌腫瘍(NET)

Market Spotlight: Neuroendocrine tumors (NET)

発行 Datamonitor Healthcare 商品コード 939993
出版日 ページ情報 英文 43 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=107.71円で換算しております。
注目市場の分析:神経内分泌腫瘍(NET) Market Spotlight: Neuroendocrine tumors (NET)
出版日: 2020年04月30日 ページ情報: 英文 43 Pages
概要

Datamonitor Healthcare は、2019年において世界で約531,400件の神経内分泌腫瘍(NET)症例が発生したと推定しており、その数は2028年までに639,200件に増加すると予測しています。2019年におけるNETの大部分は、悪性カルチノイド腫瘍または神経内分泌癌でした。

当レポートでは、神経内分泌腫瘍(NET)の主な上市薬・パイプライン薬、近年の動きとアナリストの見解、臨床試験、成功の可能性、近い将来の動き・規制の動向、特許情報、10年間の発生率予測、ライセンス供与・資産取得取引、および医薬品別の収益予測などについて分析しています。

概要

要点

疾患の背景

  • サブタイプ別

治療

  • 手術
  • 肝動脈塞栓術
  • ソマトスタチン類似体
  • インターフェロンアルファ(IFN-アルファ)
  • 化学療法
  • 放射線治療
  • 標的療法
  • 緩和ケア

疫学

  • 発生率の調査手法
  • 疾患の定義
  • 有病率の調査手法

上市薬

パイプライン薬

近年の動き・アナリストの見解

  • TBR-760

主な規制の動き

  • RadioMedix、PET診断薬のレビューを優先
  • University of Iowa のPETセンターがNME承認を取得

成功確率

ライセンシング・資産買収取引

親特許

収益機会

臨床試験環境

  • スポンサー:ステイタス別
  • スポンサー:フェーズ別
  • 近年の動き

文献

付録

図表

LIST OF FIGURES

  • Figure 1: Trends in incident cases of NETs, 2019-28
  • Figure 2: Incident cases of NETs, by tumor type, 2019
  • Figure 3: Overview of pipeline drugs for NETs in the US
  • Figure 4: Pipeline drugs for NETs, by company
  • Figure 5: Pipeline drugs for NETs, by drug type
  • Figure 6: Pipeline drugs for NETs, by classification
  • Figure 7: Probability of success in the NETs pipeline
  • Figure 8: Licensing and asset acquisition deals in NETs, 2015-20
  • Figure 9: Parent patents in NETs
  • Figure 10: Clinical trials in NETs
  • Figure 11: Top 10 drugs for clinical trials in NETs
  • Figure 12: Top 10 companies for clinical trials in NETs
  • Figure 13: Trial locations in NETs
  • Figure 14: NETs trials status
  • Figure 15: NETs trials sponsors, by phase

LIST OF TABLES

  • Table 1: Incident cases of NETs, 2019-28
  • Table 2: Five-year prevalent cases of NETs, 2019-28
  • Table 3: Marketed drugs for NETs
  • Table 4: Pipeline drugs for NETs in the US
  • Table 5: TBR-760 for NETs (January 3, 2019)
  • Table 6: Historical global sales, by drug ($m), 2014-18
  • Table 7: Forecasted global sales, by drug ($m), 2020-24
目次
Product Code: DMKC0184311

This Market Spotlight report covers the Neuroendocrine Tumors market, comprising key marketed and pipeline drugs, recent events and analyst opinion, clinical trials, probability of success, upcoming and regulatory events, patent information, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways:

  • Datamonitor Healthcare estimates that in 2019, there were approximately 531,400 incident cases of neuroendocrine tumors (NETs) worldwide, and forecasts that number to increase to 639,200 incident cases by 2028. Worldwide, the majority of NETs in 2019 were malignant carcinoid tumors or neuroendocrine carcinomas. The approved drugs in the NETs space focus on targets such as norepinephrine (noradrenaline), radiopharmaceutical, mammalian target of rapamycin/mTORC, tyrosine hydroxylase, somatostatin receptors, FMS-like tyrosine kinase 3, KIT/c-KIT, platelet-derived growth factor receptor, VEGF receptor, ganglioside GD2, and tryptophan hydroxylase. These drugs are predominantly administered via the oral, intravenous, and subcutaneous routes, while one product is available in an intramuscular formulation
  • The majority of industry-sponsored drugs in active clinical development for NETs are in Phase I. Therapies in the pipeline for NETs focus on a wide variety of targets. The largest proportion of these therapies are administered intravenously, with the remainder being oral, subcutaneous, intranasal, and intratumoral formulations.
  • The overall likelihood of approval of a Phase I solid tumors asset is 5.6%, and the average probability a drug advances from Phase III is 42.5%. Drugs, on average, take 9.4 years from Phase I to approval, compared to 9.2 years in the overall oncology space.
  • There have been only seven licensing and asset acquisition deals involving NET drugs during 2015-20. The $115m exclusive licensing agreement signed in November 2017 between NanoCarrier and VBL Therapeutics for the development, commercialization, and supply of VB-111 in Japan was the only deal with a disclosed value.
  • The distribution of clinical trials across Phase I-IV indicates that the majority of trials for NETs have been in the early and midphases of development, with 77% of trials in Phase I-II, and only 23% in Phase III-IV.
  • The US has a substantial lead in the number of NET clinical trials globally. The UK leads the major European markets, while China has the top spot in Asia.
  • Novartis has the highest number of completed clinical trials for NETs, with 19 trials. Novartis also leads industry sponsors with the highest overall number of clinical trials for NETs, followed by Ipsen.

TABLE OF CONTENTS

OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND

  • Subtypes

TREATMENT

  • Surgery
  • Hepatic artery embolization
  • Somatostatin analogs
  • Interferon-alpha (IFN-alpha)
  • Chemotherapy
  • Radiation therapy
  • Targeted therapy
  • Palliative care

EPIDEMIOLOGY

  • Incidence methodology
  • Disease definition
  • Prevalence methodology

MARKETED DRUGS

PIPELINE DRUGS

RECENT EVENTS AND ANALYST OPINION

  • TBR-760 for NETs (January 3, 2019)

KEY REGULATORY EVENTS

  • RadioMedix Eyes Priority Review For PET Diagnostic Agent
  • University of Iowa PET Center Earns NME Approval

PROBABILITY OF SUCCESS

LICENSING AND ASSET ACQUISITION DEALS

PARENT PATENTS

REVENUE OPPORTUNITY

CLINICAL TRIAL LANDSCAPE

  • Sponsors by status
  • Sponsors by phase
  • Recent events

BIBLIOGRAPHY

  • Prescription information

APPENDIX